Breve descripción
The main purpose of this phase 3 randomized, placebo controlled, double-blind clinical trial is to evaluate the efficacy of mezagitamab as compared to placebo as add-on therapy in participants receiving stable background SOC therapy for primary IgAN.
To learn more, please use this link: https://amigastudy.com/?utm_source=4e63992a-4f5e-edad-8688-d9bd36f33aac&utm_medium=WebsitePosting
Estimated Enrollment
347
Estimated End Date
October 2027
Trial is for people with
Nefropatía por IgA
Study Goal
Change from Baseline in Proteinuria at Week 36.
What is involved for the patient?
Participants will receive mezagitamab or placebo injections, SC for approximately 22 weeks in each 52-week period.
About the drug or intervention
Mezagitamab